1. Current status and research progress of oncolytic virus
- Author
-
Yingyu Chen, Mengyuan Tao, Xuwei Wu, Zheng Tang, Yinfu Zhu, Kunxiang Gong, Yinger Huang, and Wenbo Hao
- Subjects
Oncolytic virus ,Malignant tumor ,Immunotherapy ,Genetic modification ,Tumor microenvironment ,Systemic administration ,Pharmacy and materia medica ,RS1-441 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Oncolytic viruses (OVs) are natural or genetically recombinant viruses that selectively infect and kill tumor cells without affecting normal cell growth. As a novel type of immunotherapy, OVs have been shown to activate antitumor immune responses, regulate the tumor microenvironment, and enhance the efficacy of immune checkpoint inhibitors. In this review article, we discuss the latest research on the characteristics, antitumor mechanisms, and status of OV research. In terms of mechanism of action, after targeting tumor cells, OVs not only directly lyse tumor cells but also exert antitumor effects through indirect approaches. As an emerging cancer treatment, OVs face challenges that need to be overcome. Finally, we summarize the challenges and prospects for the future application of OVs.
- Published
- 2024
- Full Text
- View/download PDF